2020年医药创新市场前景及CRO行业的发展探讨  

Discussion on Prospect of Pharmaceutical Innovation Market and Development of CRO Industry in 2020

作　　者：傅鹏[1] 路江杰 孙双勇[1] FU Peng;LU Jiangjie;SUN Shuangyong(TIPR New Drug Assessment Co.,Ltd.,Tianjin 300301,China;Hefei Tianmai Biotechnology Development Co.,Ltd.,Hefei 230601,Anhui Province,China)

机构地区：[1]天津药物研究院新药评价有限公司,天津300301 [2]合肥天麦生物科技发展有限公司,安徽合肥230601

出　　处：《天津科技》2020年第5期94-96,共3页Tianjin Science & Technology

摘　　要：医药产业是我国支柱产业之一,各级地方政府也不断出台扶持政策来推动医药产业发展,分析国家医药政策持续调整对医药创新市场前景的影响,同时指出,近年来一级市场融资活跃,科创板、港股为创新型医药企业拓宽了融资渠道,随着医药产业链各个环节的投资机遇提升,越来越多创新药企将研发和评价工作转移给外部研发服务公司,未来10年医药行业领域最优赛道医药研发外包(CRO)企业将借势腾飞。The pharmaceutical industry is one of the pillar industries in China.Local governments at all levels have also issued supportive policies to promote the development of the pharmaceutical industry.The impact of continuous adjustment of national pharmaceutical policies on the prospects of the pharmaceutical innovation market is analyzed.With active financing in the primary market,the science and innovation board and Hong Kong stocks have broadened financing channels for innovative pharmaceutical enterprises and promoted investment opportunities in all aspects of the pharmaceutical industry chain.More and more innovative pharmaceutical enterprises transfer their R&D and evaluation work to external R&D service companies.In the next 10 years,the optimal track Contract Research Organization(CRO)in pharmaceutical industry will take advantage of this momentum to take off.

关 键 词：创新药 “4+7”带量采购 上市药物持有人制度(MAH) 医药研发外包(CRO) 新冠肺炎疫情 

分 类 号：R95[医药卫生—药学]